UBS raised the firm’s price target on Kodiak Sciences (KOD) to $80 from $50 and keeps a Buy rating on the shares. UBS is bullish on both Tarcocimab VEGF and IL6, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences’ Zenkuda Shows Strong Phase 3 GLOW2 Results
- Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright
- Kodiak Sciences price target raised to $56 from $39 at Jefferies
- Midday Fly By: Corebridge to merge with Equitable
- Video: Memory stocks slipping amid worries about Google compression technique